Tylosin market - Size, Share, Trends, and
Forecast to 2026
Tylosin is an antibiotic that belongs to the class of macrolide antibiotics. It functions by binding
to 50S ribosomal subunit and then interacts with 23S RNA thereby blocking aminoacyl-tRNA,
which in turn inhibits protein synthesis. Tylosin is manufactured by fermentation of the
bacterium— Streptomyces fradiae and is most effective against gram-positive bacteria compared
to gram negative bacteria. The antibiotics is used to treat various infections in animals and
respiratory infections in animals caused by Pasteurella multocida, Mannheimia haemolytica, and
Haemophilus spp.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2061
According to a report by Canadian Food Inspection Agency, 2014, 11 concentrations of tylosin
used for therapeutic purposes, range from 44 mg kg-1 to 110 mg kg-1 feed. Moreover, tylosin
is used in pigs to treat porcine proliferative enteropathy caused by Lawsonia intracellularis — a
Gram-negative bacterium. Agriculture grade Tylosin consists of 80-90% tylosin A, with smaller
amounts of tylosin B, tylosin C, and tylosin D. Around 29% of the active tylosin can be
recovered in fecal samples in animals that receive tylosin, orally.
Market Dynamics
The global Tylosin market is expected to witness significant growth over the forecast period,
owing to rising demand for Tylosin in livestock industry. For instance, according to a study by
Ministry for Primary Industries, New Zealand 2016, Tylosin accounted for over 83% of
macrolide and lincosamide sales during 2011 and 2014 and the trend is expected to continue
over the forecast period.
Moreover, certain mergers and acquisitions are expected to boost the market growth over the
forecast period. For instance, Eily, Lilly, and Company acquired Novartis Animal Health in